251 related articles for article (PubMed ID: 8320247)
1. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
Ladowski JS; Dillon T; Schatzlein MH; Peterson AC; Deschner WP; Beatty L; Sullivan M; Scheeringa RH; Clark WR
J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
[TBL] [Abstract][Full Text] [Related]
2. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
Malinow L; Walker J; Klassen D; Oldach D; Schweitzer E; Bartlett ST; Weir MR
Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
[TBL] [Abstract][Full Text] [Related]
3. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
Hariharan S; Alexander JW; Schroeder TJ; First MR
Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of replacing Minnesota antilymphocyte globulin with ATGAM.
Lum CT; Umen AJ; Kasiske B; Goerdt P; Heim-Duthoy KL; Andersen RC; Odland MD; Ney AL; Jacobs DM; Rao KV
Transplantation; 1995 Feb; 59(3):371-6. PubMed ID: 7871567
[TBL] [Abstract][Full Text] [Related]
5. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.
Indudhara R; Novick AC; Hodge E; Goormastic M; Papajcik D; Mastroianni B; Cook D
Urology; 1996 Jun; 47(6):807-12. PubMed ID: 8677568
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation--increased morbidity with OKT3.
Macdonald PS; Mundy J; Keogh AM; Chang VP; Spratt PM
Transplantation; 1993 Jan; 55(1):110-6. PubMed ID: 8380508
[TBL] [Abstract][Full Text] [Related]
7. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM
Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Minnesota antilymphoblast globulin and Upjohn antithymocyte globulin for induction immunosuppression of human renal allografts.
Pescovitz MD; Book BK; Milgrom ML; Leapman SB; Petersen B; Filo RS
Surgery; 1994 Oct; 116(4):811-8. PubMed ID: 7940183
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.
Costanzo-Nordin MR; O'Sullivan EJ; Johnson MR; Winters GL; Pifarre R; Radvany R; Zucker MJ; Scanlon PJ; Robinson JA
J Heart Transplant; 1990; 9(3 Pt 2):306-15. PubMed ID: 2113094
[TBL] [Abstract][Full Text] [Related]
11. Comparative trial of immunoprophylaxis with RATG versus OKT3.
Griffith BP; Kormos RL; Armitage JM; Dummer JS; Hardesty RL
J Heart Transplant; 1990; 9(3 Pt 2):301-5. PubMed ID: 2113093
[TBL] [Abstract][Full Text] [Related]
12. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials.
Ross DJ; Jordan SC; Nathan SD; Kass RM; Koerner SK
Chest; 1996 Apr; 109(4):870-3. PubMed ID: 8635362
[TBL] [Abstract][Full Text] [Related]
13. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
Bailey TC; Powderly WG; Storch GA; Miller SB; Dunkel JD; Woodward RS; Spitznagel E; Hanto DW; Dunagan WC
Am J Kidney Dis; 1993 Feb; 21(2):196-201. PubMed ID: 8381577
[TBL] [Abstract][Full Text] [Related]
14. HLA-DR incompatibility predicts heart transplant rejection independent of immunosuppressive prophylaxis.
Costanzo-Nordin MR; Fisher SG; O'Sullivan EJ; Johnson M; Heroux A; Kao W; Mullen GM; Radvany R; Robinson J
J Heart Lung Transplant; 1993; 12(5):779-89. PubMed ID: 8241215
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic cytolytic therapy in heart transplantation: monoclonal versus polyclonal antibody therapy.
Laske A; Gallino A; Schneider J; Bauer EP; Carrel T; Pasic M; von Segesser LK; Turina MI
J Heart Lung Transplant; 1992; 11(3 Pt 1):557-63. PubMed ID: 1610864
[TBL] [Abstract][Full Text] [Related]
16. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect.
Heifets M; Saeed MI; Parikh MH; Sierka D; Kumar MS
Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580
[TBL] [Abstract][Full Text] [Related]
17. Comparison of polyclonal antibody sera for early prophylaxis following cardiac transplantation.
Bolling SF; Stirling MC; Miska P; Deeb GM
J Surg Res; 1989 Oct; 47(4):292-6. PubMed ID: 2671502
[TBL] [Abstract][Full Text] [Related]
18. Rabbit antithymocyte globulin. A 10-year experience in cardiac transplantation.
Copeland JG; Icenogle TB; Williams RJ; Rosado LJ; Butman SM; Vasu MA; Sethi GK; McDonald AN; Klees E; Rhenman MJ
J Thorac Cardiovasc Surg; 1990 May; 99(5):852-60. PubMed ID: 2329823
[TBL] [Abstract][Full Text] [Related]
19. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts.
Menkis AH; Powell AM; Novick RJ; McKenzie FN; Kostuk WJ; Pflugfelder PW; Brown JE; Rochon J; Chow LH; Stiller C
J Heart Lung Transplant; 1992; 11(3 Pt 1):569-76. PubMed ID: 1610866
[TBL] [Abstract][Full Text] [Related]
20. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
